Cassava Sciences Stock Price, News & Analysis

Cassava Sciences (Nasdaq: SAVA) is set to join a virtual panel on innovative treatment approaches for Alzheimer’s disease on May 26 at 11:00am Eastern Time. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group, featuring Remi Barbier, President & CEO of Cassava Sciences. Alzheimer's, affecting approximately 50 million people globally, is a progressive brain disorder without current drug therapies to halt its advancement. The annual global cost of dementia exceeds $1 trillion.

Cassava Sciences has secured a $2.7 million research grant from the National Institutes of Health (NIH) to fund clinical readiness activities for its Phase 3 program with simufilam, a drug candidate targeting Alzheimer's disease. This grant follows a peer review process which validated the clinical and scientific data of simufilam. The company aims to leverage this funding to advance its commitment to developing effective treatments for Alzheimer’s, as the global dementia cost surpasses $1 trillion

Cassava Sciences, a biotechnology company focused on Alzheimer’s disease, has initiated a Cognition Maintenance Study (CMS) to assess the effects of simufilam in patients with the condition. The randomized, controlled study aims to enroll 100 participants and evaluate cognitive changes over six months between those who continue and discontinue treatment. Simufilam targets neurodegeneration and inflammation, and early results have shown positive cognitive outcomes. The study is part of the company’s broader strategy to advance simufilam towards Phase 3 trials.

Cassava Sciences, Inc. (Nasdaq: SAVA) will participate in the B. Riley Securities’ Neuroscience Conference on April 28-29, 2021. Remi Barbier, President & CEO, is set to engage in a virtual Fireside Chat on April 28 at 2:30 PM Eastern. The conference will address topics in neurodegeneration and neuropsychiatry, featuring prominent companies in the field. An archived replay of the chat will be available on Cassava's website for about 90 days post-event. For details, visit CassavaSciences.com.

AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, a clinical-stage biotechnology company focused on Alzheimer’s disease, has been invited to the Sachs 4th Annual Neuroscience Innovation Forum, taking place virtually from April 28-30, 2021. The National Institute on Aging of the NIH will feature Cassava's scientific program during this event. Dr. Lindsay Burns, Senior VP of Neuroscience, will present a 10-minute overview of their Alzheimer’s program. The webcast will be available on Cassava’s website starting April 28 at 8:30 AM ET.

Cassava Sciences (SAVA) reported its Q1 2021 financial results, highlighting a robust cash position of $282.2 million as of March 31, 2021. The company is advancing the pivotal Phase 3 program for simufilam, aimed at treating Alzheimer’s disease, with an expected initiation in the 2nd half of 2021. An interim analysis of a 9-month open-label study will be presented at the Alzheimer’s Association International Conference in July 2021. Initial results indicate improved cognition scores for patients undergoing 6 months of treatment.

Cassava Sciences (SAVA) reported its financial results for the year ended December 31, 2020, highlighting a cash position of approximately $280 million as of February 2021. The company revealed that its lead drug candidate, simufilam, showed potential in improving cognition scores in Alzheimer’s patients after 6 months of treatment. The company plans to announce more data from a 12-month study mid-2021 and expects to initiate pivotal Phase 3 clinical trials later this year. Financially, the net loss for 2020 was $6.3 million, with a significant increase in cash from stock sales and NIH grants.

Cassava Sciences (Nasdaq: SAVA) has entered a drug supply agreement with Evonik Industries for simufilam, a treatment candidate for Alzheimer’s disease. The agreement facilitates the supply of large-scale, clinical-grade simufilam as Cassava progresses in its mission to develop solutions for chronic neurodegenerative diseases. The partnership highlights a commitment to enhancing the quality of life for Alzheimer's patients. Evonik, a leading contract development and manufacturing organization, aims to leverage its expertise to support Cassava's goals.

Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, is set to present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The management team will engage in virtual one-on-one meetings with analysts and investors. The presentation will be available on-demand from 7:00 AM ET on March 9 through the conference portal. Their lead drug candidate, Simufilam, aims to restore normal function of disrupted brain proteins associated with Alzheimer's.

For more details, visit www.CassavaSciences.com.